source
- RA Capital leads $175 million round for Oak Hill Bio to revive Roche’s Angelman syndrome drugRA Capital and other investors have committed $175 million to Oak Hill Bio, a new biotech aiming to revive a previously shelved experimental therapy for Angelman syndrome originally developed by Ro…
- Biotech confidence surges in 2026 as China leads growth and deal activity spikesIndustry observers noted a marked shift in tone at two major 2026 biotech gatherings – the DIA China meeting in Shanghai and the BIO International Convention in San Diego – where participants expre…